The estimated Net Worth of Stephen F. Betz is at least $8.49 Millón dollars as of 26 August 2024. Dr Betz owns over 3,000 units of Crinetics Pharmaceuticals Inc stock worth over $3,532,062 and over the last 3 years he sold CRNX stock worth over $4,958,808.
Dr has made over 44 trades of the Crinetics Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of CRNX stock worth $159,570 on 26 August 2024.
The largest trade he's ever made was selling 16,500 units of Crinetics Pharmaceuticals Inc stock on 5 November 2021 worth over $462,990. On average, Dr trades about 3,783 units every 22 days since 2021. As of 26 August 2024 he still owns at least 69,611 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Dr Betz stock trades at the bottom of the page.
Dr. Stephen F. Betz Ph.D. is the Founder & Chief Scientific Officer at Crinetics Pharmaceuticals Inc.
Dr D is 55, he's been the Founder & Chief Scientific Officer of Crinetics Pharmaceuticals Inc since . There are 10 older and 6 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
Stephen's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen y Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: